Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Inclusion Criteria: * Voluntary written informed consent form before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care * Diagnosis of B-type NHL or with multiple myeloma and eligible for autologous transplantation * No more than 3 prior regimens of chemotherapy (Rituximab is not considered chemotherapy) and 4 weeks out of Bortezomib treatment for MM * Karnofsky performance status of \> 50% * The patient has recovered from all acute toxic effects of prior chemotherapy * White blood cell (WBC) \> 3.0 x 10\^9/L * Absolute neutrophil count \> 1.5 x 10\^9/L * Platelet count \> 100 x 10\^9/L * Serum creatinine =\< 2.2 * Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate transaminase (SGPT) less than two times the upper limit of normal (ULN) * Total bilirubin less than two times the ULN * Left ventricle ejection fraction \> 50% (by normal echocardiogram \[ECHO\] or multi gated acquisition scan \[MUGA\] scan) * Diffusing capacity of the lung for carbon monoxide (DLCO) \> 50% * Forced vital capacity \> 50% of predicted * Negative for human immunodeficiency virus (HIV) * Female subject is either post-menopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential , agree to use 2 effective methods of birth control (i.e., a hormonal contraceptive, intra-uter…